Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors

NCT04979390 | Unknown Phase 1

• 1 other identifier: SHR-1316-I-103
• Study Type: interventional
• Target: 15
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of the new formulation SHR-1316 in subjects with advanced tumors.

Conditions

Tumor

Outcome Measures

Primary Outcomes (10)

• The incidence and severity of adverse events/serious adverse events (based on NCI-CTC AE 5.0)

  approximately 1 year

• Maximum plasma concentration (Cmax)

  approximately 1 year

• Time to maximum concentration (Tmax)

  approximately 1 year

• Area under the concentration-time curve from time zero to time（AUC0-t）

  approximately 1 year

• Area under the concentration-time curve extrapolated to infinity (AUC0-∞.)

  approximately 1 year

• Elimination half-life (t1/2)

  approximately 1 year

• Clearance (CL)

  approximately 1 year

• Volume of distribution (Vz)

  approximately 1 year

• Trough concentration (Cmin)

  approximately 1 year

• Accumulatio of ratio (Rac)

  approximately 1 year

Secondary Outcomes (6)

• Immunogenicity of SHR-1316

  approximately 1 year

• Objective response rate (ORR)

  approximately 1 year

• Progression-free survival (PFS)

  approximately 1 year

• Duration of response (DoR)

  approximately 1 year

• Disease control rate (DCR)

  approximately 1 year

Study Arms (1)

Treatment group

EXPERIMENTAL

Drug: SHR-1316

Interventions

SHR-1316 DRUG

SHR-1316 administrated intravenously (IV) at protocol defined dose levels

Treatment group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years.
• Histologically or cytologically confirmed advanced cancer in patients who are fail to current standard therapy or lack of effective therapy.
• Estimated life expectancy ≥12 weeks.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate organ functions.
• If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment dose.
• Patients must be willing and able to provide written informed consent prior to the performance of any study-specific procedure.

You may not qualify if:

• Known history of hypersensitivity to any components of the SHR-1316 product.
• Patient- Prior treatment with the following agents:
• "Check-point inhibitors", including Programmed death receptor-1 (PD-1), PD-L1;
• Receipt of investigational agents within 4 weeks prior to study treatment;
• Current treatment on another therapeutic clinical trial, unless the observational (non-interventional) clinical trials or follow-up of interventional clinical trials;
• Any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, target therapy, biotherapy or tumor embolization), administered within 4 weeks prior to study treatment; or within 6 weeks in the case of certain therapies (e.g., mitomycin C and nitrosoureas). Any such, unless discussed and explained with the sponsor;
• Anticipated need for any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, or biotherapy) during SHR-1316 treatment; except palliative radiotherapy;
• Receipt of any anti-cancer vaccines; receipt of immunomodulatory drugs within 4 weeks prior to study treatment; topical, nasal spray and inhaled corticosteroids as well as systemic steroid therapy in physiological doses (such as: prednisone ≤10 mg/day) are acceptable.
• Patients have unrecovered (ie, to NCI CTCAE grade ≤1) from all toxicity associated with previous treatments (exception: patients may enter with continuing alopecia irrespective of CTCAE grade; grade 2 peripheral nerve diseases).
• Known Active central nervous system (CNS) metastases; Patients who had previously received brain or meningeal metastasis therapy, who were clinically stable for at least 8 weeks, and who had stopped systemic sex hormone therapy (such as： prednisone \> 10 mg/day) for more than 4 weeks were included.
• Subjects with active autoimmune disease, history of autoimmune diseases, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.
• Active or history of immune deficiency, such as human immunodeficiency virus (HIV) infection; History of organ transplantation.
• History or evidence of cardiovascular (CV) risk including any of the following: Congestive heart failure (Class \>2) as defined by the New York Heart Association functional classification system (NYHA), unstable angina pectoris, Recent (within the past 12 months) history of myocardial infarction, clinically significant supraventricular or ventricular arrhythmias need treatment or intervention.
• Patients with clinically significant ECG abnormalities (QT interval corrected for rate by Fridericia's formula \[QTcF\] \>470 msec for female and \>450 msec for male on the ECG obtained at Screening).
• Active infection that need drug intervention or an unexplained fever \>38.5°C (fever caused by cancer can be included according to the judgement of the researcher).

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

Yuya Wang

CONTACT

13918749176; yuya.wang@hengrui.com

Wen Jing

CONTACT

17721286191; wen.jing@hengrui.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: SHR-1316 administrated intravenously (IV) at protocol defined dose levels

Study Record Dates

• First Submitted: July 12, 2021
• First Posted: July 28, 2021
• Study Start: August 10, 2021
• Primary Completion: February 10, 2022
• Study Completion: July 31, 2022
• Last Updated: July 28, 2021

Record last verified: 2021-07